Alpa Laboratories Limited

As of June 30, 2026, Alpa Laboratories Limited carries a market capitalization of 1.42B, placing it among publicly traded companies globally. Its enterprise value stands at 1.42B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Alpa Laboratories Limited has 21.04M shares outstanding.

As of June 30, 2026, Alpa Laboratories Limited trades at a trailing price-to-earnings ratio of 32.67.

These figures are as of June 30, 2026. The EV/Sales ratio of 1.28 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.42B versus a market cap of 1.42B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 2.43M in revenue per employee across its workforce of 455.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Alpa Laboratories Limited recorded 15.32M in income tax expense. That works out to an effective tax rate of 25.91, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 59.10M, leaving 43.78M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Alpa Laboratories Limited's stock has declined approximately 41.72% over the past 52 weeks. The 50-day moving average sits at 60.32, while the 200-day moving average is 65.75.

Over the twelve months ended June 30, 2026, Alpa Laboratories Limited generated 1.11B in revenue and converted that into 43.78M in net income, yielding earnings per share of 2.07. EBITDA reached -10.91M, while operating income came in at -33.50M.

Over the twelve months ended June 30, 2026, Alpa Laboratories Limited posted a gross margin of 25.54, reflecting its pricing power and cost economics. The operating margin of -3.03 and net profit margin of 3.96 provide insight into operational efficiency.